Logo

5th Gene Therapy for Ophthalmic Disorders Summit

 

5th Gene Therapy for Ophthalmic Disorders Summit

14 14 people viewed this event.

Ophthalmic drug developers are unlocking the full potential of gene therapy. Crucial lessons learnt from both clinical successes and failures, coupled with recent improvements in development and delivery, means that the space is poised to capitalize on the significant potential of the eye as a target for genetic medicine approaches.

 

Time: 8:00 AM – 5:00 PM

Venue details: Wyndham Boston Beacon Hill, 5 Blossom Street, Boston, Massachusetts, 02114, United States

Prices: USD 2599.00 – USD 5097.00

Speakers: Abraham Scaria, Chief Scientific Officer, Beacon Therapeutics, Adam Silverman, Vice President – Protein Sciences, Spotlight Therapeutics, Aniz Girach, Chief Medical Officer, Splice Bio, Arun Upadhyay, Chief Scientific Officer, Head of Research and Development, Ocugen, Christopher Chavez, Vice President, Research and Development, Visgenx Inc., and more

Contact Person - Mara Mihailovic

Email - info@hansonwade.com

Organizer - Hanson Wade

Event Website
 

Date

10 Sep. 2024
12 Sep. 2024
 

City

Boston
 

Country

United States of America
 

Topic Area

Health and Medicine

Share With Colleagues